카나프테라퓨틱스

0082N0KOSDAQ자연과학 및 공학 연구개발업

47.8 / 100

Reference Date: 2026-07-24

Financial Score16.5 / 40

News Sentiment17.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but PBR raises overvaluation concerns. Plunged 18.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Canapharmaceuticals is an innovative biopharmaceutical company developing novel drugs for oncology and ophthalmic diseases using human genome-based technology. The company has a diverse pipeline of seven projects, including bispecific antibodies, ADCs, and synthetic drugs, and has secured significant revenue through early-stage technology transfers and co-development partnerships with major pharmaceutical firms in South Korea.

Number of Employees

23people

Average Salary

55.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

13.95Industry Average 2.520.0Point

5.5x industry avg (risky)

ROE

—Industry Average -32.093.5Point

Debt Ratio

5.73Industry Average 7.314.0Point

In line with industry avg

Trend 5.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

2.0 / 4

Detailed News Sentiment

5 totalPositive 3Neutral 0Negative 2Average Sentiment Score 69

Negative
J&J도 접은 지도모양위축 치료제…카나프 '이중항체' 승부수 통할까
카나프테라퓨틱스의 지도모양위축 치료제 임상 실패로 인해 기술적 난관과 시장 수용성에 대한 우려가 증가.
Positive
IPO 줄서는 아주IB 포트폴리오…하반기 엑시트 기대 커진다
아주IB투자 포트폴리오 스타트업들의 연이은 IPO 성공으로 카나프테라퓨틱스의 하반기 엑시트 기대감이 높아짐.
Negative
[증권사 IPO 재편]① 한투證, 빅딜 수임보다 어려워진 '완주'
한국투자증권의 카나프테라퓨틱스 IPO 관련 복잡한 규제 환경으로 인해 상장 과정이 어려워질 전망.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 13,020Won52-week high 52,20052-week low 11,230

1-month return0.0Point

1m -18.47% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-20